General Information of Drug (ID: DMR2L6X)

Drug Name
PMID14640538C3 Drug Info
Synonyms mergepta; 2-Mmgetpa; 2-mercaptomethyl-3-guanidinoethylthiopropanoic acid; Mergepta; Mergetpa; 77102-28-4; AC1Q5S0I; AC1L3X6V; AC1Q50E9; GTPL8675; CTK8D5675; LS-177336
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
123726
CAS Number
CAS 77102-28-4
TTD Drug ID
DMR2L6X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Carboxypeptidase B1 (CPB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US8710232, 8 DM1MQ7J N. A. N. A. Patented [2]
US8710232, 1 DMCNAM9 N. A. N. A. Patented [2]
US8710232, 7 DMCNS9T N. A. N. A. Patented [2]
PMID19954973C4 DMDYZE5 Discovery agent N.A. Investigative [3]
Drug(s) Targeting Carboxypeptidase B2 (CPB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-126119 DMKHM7O Cerebrovascular ischaemia 8B1Z Phase 1 [4]
UK-396082 DMFYKDX Thrombosis DB61-GB90 Phase 1 [3]
DS-1040 DMXCN37 Ischemic stroke 8B11.5Z Phase 1 [5]
SAR-104772 DMQ9ZY0 Cerebrovascular ischaemia 8B1Z Phase 1 [6]
AZD-9684 DMHA5ME Thrombosis DB61-GB90 Discontinued in Phase 2 [7]
DL-benzylsuccinic acid DMHI9ZJ Discovery agent N.A. Investigative [8]
PMID19954973C4 DMDYZE5 Discovery agent N.A. Investigative [3]
3-mercapto-2-(piperidin-3-yl)propanoic acid DMPJBNC Discovery agent N.A. Investigative [9]
6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid DMMUE05 Discovery agent N.A. Investigative [10]
3-mercapto-2-(piperidin-4-yl)propanoic acid DMYQG7A Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Arginine carboxypeptidase (CPN1) TT8V2KD CBPN_HUMAN Inhibitor [1]
Carboxypeptidase B1 (CPB1) TT4UJX5 CBPB1_HUMAN Inhibitor [1]
Carboxypeptidase B2 (CPB2) TTP18AY CBPB2_HUMAN Inhibitor [1]
Carboxypeptidase M (CPM) TTVOH2M CBPM_HUMAN Inhibitor [1]

References

1 Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
2 Imidazole derivatives used as TAFIa inhibitors. US8710232.
3 Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6.
4 TAFIa inhibitors in the treatment of thrombosis. Curr Opin Drug Discov Devel. 2008 Jul;11(4):480-6.
5 Clinical pipeline report, company report or official report of Daiichi Sankyo.
6 Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009.
7 Clinical pipeline report, company report or official report of AstraZeneca.
8 A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
9 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
10 Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg Med Chem Lett. 2004 May 3;14(9):2141-5.